[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][C][C@@H1][C][C][=Branch1][C][=O][N][Branch1][Ring2][C][Ring1][=Branch1][C@@H1][Branch1][Ring1][C][C][C][=Branch1][C][=O][N]"}, {"from": "gpt", "value": "The molecule is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016."}]